$PLPL Plandai's Products May Inhibit Prostate Cancer

New Post Public Reply Private Reply Replies (1) Message Board
jstops

[b]$PLPL[/b] Plandai's Products May Inhibit Prostate Cancer Growth


BALTIMORE, MD, [b][color=green]Jun 11, 2013[/color][/b] (Marketwired via COMTEX) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, reports that recent prostate cancer studies involving the use of green tea as a method of inhibiting prostate cancer growth demonstrate yet another major clinical market opportunity for Plandai Biotechnology Inc. (OTCQB: PLPL). Prostate cancer is the second leading cause of cancer death among men in the U.S. and the sixth leading cause of cancer death among men worldwide.

Last week at the annual ASCO (Association of Clinical Oncology) conference, a group of doctors who conducted a study of 203 men diagnosed with prostate cancer at hospitals in Europe demonstrated that polyphenol-rich foods such as green tea demonstrated multiple anti-cancer effects.


The aforementioned six-month trial is not the first to study the effect of green tea on prostate cancer. A recent two-month study at the University of California, Los Angeles (UCLA) demonstrated that the consumption of 6 cups of green tea daily might inhibit the growth of prostate cancer tumors by decreasing inflammation and stimulating cell death. The Phase 2 trial was randomized and included 67 subjects. Once again, results showed that the polyphenols routinely reached the prostate.


The key takeaway from both of these studies is that it is likely that increased bioavailability in the consumed product may result in increased efficacy. For example, instead of having trial subjects consume 6 cups of green tea daily, as was the case in the UCLA trial, it makes more sense to utilize a form of Plandai's Phytofare(TM) Catechin Complex, which is processed to deliver a highly bioavailable, antioxidant- rich botanical green tea-derived extract at a level many times that of other products available on the market. Therefore, not only would the subject reduce consumption, but the higher bioavailability could lead to greater efficacy as well.


Since a number of extended and new studies on the effect of green tea and prostate cancer are in the offing, we believe that Plandai will benefit as a likely primary source of product for the trials and these moves potentially could result in a commercially available Plandai-product used by consumers to prevent or treat prostate cancer.


Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.


About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.


A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.


About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare(TM) extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 209

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Highmark’s 2026 Rebound Has a Few Asterisks Attached

Updated Category News Views 74

The Headline Needs a Pencil, Not a Highlighter A $1.9 billion net-income figure can look downright thunderous until you separate the cash-generating engine from the accounting cargo strapped to it. Highmark Health reported $26.5 billion in revenue and $741 million in operating income for the nine months ended Sept. 30, 2026. Those are materially better numbers than the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 94

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 149

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 191

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 151

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 131

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Scatec Completes Initial Phase of Solar Power Plant Sale

Updated Category News Views 114

Scatec ASA, a heavyweight in the renewable energy arena, concluded the first phase of selling parts of its holdings in the Kalkbult, Linde, and Dreunberg solar power plants back in 2024. This deal was inked with Greenstreet 1 Proprietary Limited—a subsidiary under the STANLIB Infrastructure Fund II umbrella. Transaction Breakdown: Financials and Implications The...

Continue Reading
Taiwan Semiconductor Excels with Strong AI Demand and Profits

Updated Category News Views 227

Taiwan Semiconductor's Remarkable Performance Taiwan Semiconductor Manufacturing Co (NYSE: TSM) has recently reported outstanding financial results for the third quarter, which surpassed expectations and reflected the growing global demand for advanced microchip technologies. Investors celebrated as TSM stock saw gains following these impressive numbers, showing...

Continue Reading
China Eases Mortgage Burdens as Economy Faces Challenges

Updated Category News Views 246

The People's Bank of China (PBOC) dropped a bombshell back in mid-2024, mandating commercial banks to slash interest rates on all existing housing loans. This move was their bid to ease the financial burden on households grappling with an economy that just wouldn’t budge. You see, this wasn’t just some casual tweak; it was a strategic lifeline thrown into the...

Continue Reading
Dimethylolpropionic Acid Market Forecast: Growth Driven by Eco-Friendly Solutions

Updated Category News Views 88

Overview of the Dimethylolpropionic Acid Market The global market for dimethylolpropionic acid (DMPA) is set for substantial growth, with projections indicating an increase of USD 230.2 million from 2024 to 2028, as highlighted in recent analyses. This growth translates to a compound annual growth rate (CAGR) of 7.05%. A key factor driving this expansion is the tightening...

Continue Reading
Bowen Acquisition Corp Faces NASDAQ Delisting Risk Amid Non-Compliance

Updated Category News Views 257

Bowen Acquisition Corp's Delisting Notification from NASDAQ Bowen Acquisition Corp (NASDAQ: BOWN) has recently faced the daunting challenge of a potential delisting from the Nasdaq Global Market. The announcement came as a response to a delisting determination letter received on a notable date which has since raised concerns among investors and stakeholders alike....

Continue Reading